Potent and orally bioavailable stearoyl-CoA desaturase (SCD) inhibitors for the potential treatment of obesity and diabetes

被引：0

作者：

Koltun, Dmitry ^{[1
]}

Parkhilll, Eric Q. ^{[1
]}

Vasilevich, Natalya I. ^{[2
]}

Glushkov, Andrei I. ^{[2
]}

Zilbershtein, Timur M. ^{[2
]}

Ivanov, Aleksey V. ^{[2
]}

Zautke, Nathan A. ^{[3
]}

Brunn, Sandra A. ^{[3
]}

Mollova, Nevena ^{[4
]}

Leung, Kwan ^{[4
]}

Chisholm, Jeffrey W. ^{[3
]}

Zablocki, Jeff ^{[5
]}

机构：

[1] CV Therapeut, Dept Bioorgan Chem, Palo Alto, CA 94304 USA

[2] ASINEX Ltd, Dept Chem, Moscow 123367, Russia

[3] CV Therapeut, Dept Pharmacol Sci, Palo Alto, CA 94304 USA

[4] CV Therapeut, Dept Preclin Dev, Palo Alto, CA 94304 USA

[5] CV Therapeut, Dept Med Chem, Palo Alto, CA 94304 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2009年 / 237卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

4-MEDI

引用

页数：1

共 50 条

[21] SAR of a new series of Stearoyl-CoA desaturase inhibitors
Leclerc, Jean-Philippe
Chan, Chi-Chung
Falgueyret, Jean-Pierre
Guay, Jocelyn
Guiral, Sebastien
Huang, Zheng
Lachance, Nicolas
Li, Chun Sing
Oballa, Renata
Ramtohul, Yeeman K.
Zhang, Lei
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
[22] Characterization of the human stearoyl-coa desaturase (SCD) gene and a processed SCD pseudogene.
Zhang, L
Ge, L
Parimoo, S
Stenn, K
Prouty, S
MOLECULAR BIOLOGY OF THE CELL, 1998, 9 : 191A - 191A
[23] Stearoyl-CoA desaturase inhibitors: update on patented compounds
Liu, Gang
EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (09) : 1169 - 1191
[24] Potent and orally bioavailable stearoyl-CoA desaturase (SCD) inhibitors based on the pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one scaffold
Parkhill, Eric Q.
Koltun, Dmitry
Brunn, Sandra A.
Mollova, Nevena
Leung, Kwan
Chisholm, Jeffrey W.
Zablocki, Jeff
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
[25] Stearoyl-CoA desaturase deficiency, hypercholesterolemia, cholestasis, and diabetes
Attie, Alan D.
Flowers, Matthew T.
Flowers, Jessica B.
Groen, Albert K.
Kuipers, Folkert
Ntambi, James M.
NUTRITION REVIEWS, 2007, 65 (06) : S35 - S38
[26] 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: Part 2. Pyridazine-based analogs
Yang, Shyh-Ming
Tang, Yuting
Rano, Thomas
Lu, Huajun
Kuo, Gee-Hong
Gaul, Michael D.
Li, Yaxin
Ho, George
Lang, Wensheng
Conway, James G.
Liang, Yin
Lenhard, James M.
Demarest, Keith T.
Murray, William V.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (05) : 1437 - 1441
[27] 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: Urea-based analogs
Yang, Shyh-Ming
Tang, Yuting
Zhang, Rui
Lu, Huajun
Kuo, Gee-Hong
Gaul, Michael D.
Li, Yaxin
Ho, George
Conway, James G.
Liang, Yin
Lenhard, James M.
Demarest, Keith T.
Murray, William V.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (24) : 6773 - 6776
[28] The role of stearoyl-CoA desaturase in obesity, insulin resistance, and inflammation
Sampath, Harini
Ntambi, James M.
YEAR IN DIABETES AND OBESITY, 2011, 1243 : 47 - 53
[29] Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity
Iida, Tetsuya
Ubukata, Minoru
Mitani, Ikuo
Nakagawa, Yuichi
Maeda, Katsuya
Imai, Hiroto
Ogoshi, Yosuke
Hotta, Takahiro
Sakata, Shohei
Sano, Ryuhei
Morinaga, Hisayo
Negoro, Tamotsu
Oshida, Shinichi
Tanaka, Masahiro
Inaba, Takashi
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 158 : 832 - 852
[30] Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1
Jiang, GQ
Li, ZH
Liu, F
Ellsworth, K
Dallas-Yang, Q
Wu, M
Ronan, J
Esau, C
Murphy, C
Szalkowski, D
Bergeron, R
Doebber, T
Zhang, BB
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (04): : 1030 - 1038

← 1 2 3 4 5 →